MCID: KRT006
MIFTS: 53

Keratoconjunctivitis

Categories: Eye diseases, Infectious diseases, Neuronal diseases

Aliases & Classifications for Keratoconjunctivitis

MalaCards integrated aliases for Keratoconjunctivitis:

Name: Keratoconjunctivitis 12 54 43 15 71 32

Classifications:



External Ids:

Disease Ontology 12 DOID:9368
ICD9CM 34 370.40
MeSH 43 D007637
NCIt 49 C34744
SNOMED-CT 67 88151007
ICD10 32 B30.0 H16.2
UMLS 71 C0022573

Summaries for Keratoconjunctivitis

MalaCards based summary : Keratoconjunctivitis is related to vernal keratoconjunctivitis and keratoconjunctivitis sicca. An important gene associated with Keratoconjunctivitis is RNASE3 (Ribonuclease A Family Member 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Tocopherol and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and t cells, and related phenotypes are hematopoietic system and digestive/alimentary

Wikipedia : 74 Keratoconjunctivitis is inflammation ("-itis") of the cornea and... more...

Related Diseases for Keratoconjunctivitis

Diseases related to Keratoconjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 806)
# Related Disease Score Top Affiliating Genes
1 vernal keratoconjunctivitis 34.5 RNASE3 IL5 IL4 IL13 CCL24 CCL11
2 keratoconjunctivitis sicca 34.4 TNF NGF MUC5AC IL4
3 neurotrophic keratoconjunctivitis 33.9 NGF MUC5AC
4 atopic keratoconjunctivitis 33.4 RNASE3 MUC5AC MUC16 IL5 IL4 IL3
5 dry eye syndrome 32.6 TNF NGF MUC5AC IL6
6 tropical spastic paraparesis 32.4 MMP9 IL6 IL2 IL17A IFNG
7 keratitis, hereditary 31.4 TNF IL6 IL17A
8 cytokine deficiency 31.3 IL5 IL13
9 ige responsiveness, atopic 31.1 RNASE3 IL5 IL4 IL13 IFNG
10 dacryoadenitis 31.0 IL4 IL17A IL13
11 corneal ulcer 30.9 NGF MUC5AC MMP9 CCL11
12 dysentery 30.9 TNF IL6 CXCL8
13 graft-versus-host disease 30.9 TNF IL6 IL2 IFNG
14 thyroiditis 30.8 TNF IL6 IL4 IL2
15 vernal conjunctivitis 30.8 RNASE3 MUC5AC IL4 IFNG
16 hypopyon 30.7 TNF IL6 IL17A
17 chlamydia pneumonia 30.7 TNF IL6 CXCL8
18 papillary conjunctivitis 30.7 IL6 IL4 CXCL8 CCL24 CCL11
19 rosacea 30.7 TNF MMP9 IL6 CXCL8
20 keratopathy 30.6 TNF IL4 ICAM1 CXCL8 AIRE
21 acquired immunodeficiency syndrome 30.6 TNF IL6 IL2 IFNG ICAM1
22 iridocyclitis 30.6 TNF IL6 IL17A
23 blepharitis 30.5 TNF MUC5AC MUC16 MMP9 IL6 IL4
24 trachoma 30.5 TNF IL6 IL4 IL17A
25 conjunctivochalasis 30.5 MMP9 IL6 CXCL8
26 pharyngitis 30.4 TNF IL6 CXCL8
27 chlamydia 30.4 TNF IL6 IL5 IL4 IL17A IFNG
28 chickenpox 30.4 TNF IL6 IL4 IL2 IFNG
29 endophthalmitis 30.4 TNF IL6 ICAM1 CXCL8
30 giant papillary conjunctivitis 30.4 RNASE3 IL6 IL4 CXCL8 CCL24 CCL11
31 scleritis 30.4 TNF MMP9 IL5 IL4 IFNG
32 multicentric castleman disease 30.4 IL6 IL5 IFNG
33 optic neuritis 30.4 TNF IL6 CXCL8
34 iritis 30.3 TNF IL6 IL17A
35 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.3 IL17A IFNG AIRE
36 vaccinia 30.3 TNF IL6 IL2 ICAM1
37 toxoplasmosis 30.3 TNF IL6 IL5 IL4 IFNG
38 cryoglobulinemia 30.3 TNF IL6 IFNG
39 ocular cicatricial pemphigoid 30.3 RNASE3 NGF IL4
40 pollen allergy 30.3 RNASE3 IL5 IL3 IL13 ICAM1
41 purpura 30.2 TNF IL6 IL4 IFNG
42 exanthem 30.2 TNF IL6 IL2 IFNG CXCL8
43 pertussis 30.2 TNF IL6 CXCL8 CCL11
44 mastocytosis 30.1 IL6 IL4 IL3 IL13
45 bronchopneumonia 30.1 TNF IL6 CXCL8
46 allergic conjunctivitis 30.1 TNF RNASE3 IL5 IL4 IL2 IL13
47 common variable immunodeficiency 30.1 TNF IL6 IL5 IL4 IL2 IFNG
48 haemophilus influenzae 30.1 TNF CXCL8
49 meningoencephalitis 30.0 TNF NGF IL6 IL4
50 retinal vein occlusion 30.0 TNF IL6 CXCL8

Comorbidity relations with Keratoconjunctivitis via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Keratoconjunctivitis:



Diseases related to Keratoconjunctivitis

Symptoms & Phenotypes for Keratoconjunctivitis

MGI Mouse Phenotypes related to Keratoconjunctivitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.27 AIRE CCL11 CCL24 ICAM1 IFNG IL13
2 digestive/alimentary MP:0005381 10.26 AIRE ICAM1 IFNG IL13 IL17A IL2
3 homeostasis/metabolism MP:0005376 10.25 AIRE ICAM1 IFNG IL13 IL17A IL2
4 immune system MP:0005387 10.25 AIRE CCL11 CCL24 ICAM1 IFNG IL13
5 integument MP:0010771 10.02 ICAM1 IFNG IL13 IL17A IL4 IL6
6 neoplasm MP:0002006 9.92 AIRE ICAM1 IFNG IL2 IL5 IL6
7 no phenotypic analysis MP:0003012 9.86 AIRE IFNG IL13 IL17A IL2 IL4
8 reproductive system MP:0005389 9.85 AIRE CD46 IFNG IL13 IL2 IL4
9 respiratory system MP:0005388 9.73 AIRE CCL11 CCL24 IFNG IL13 IL17A
10 vision/eye MP:0005391 9.36 AIRE CD46 ICAM1 IFNG IL2 IL4

Drugs & Therapeutics for Keratoconjunctivitis

Drugs for Keratoconjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 226)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
2
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
3
Povidone Approved Phase 4 9003-39-8
4
Histamine Approved, Investigational Phase 4 51-45-6 774
5
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
6
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
7
Glycerol Approved, Investigational Phase 4 56-81-5 753
8
Fluorometholone Approved, Investigational Phase 4 426-13-1 9878
9
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
10
Dipivefrin Approved Phase 4 52365-63-6 3105
11
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
12
Ofloxacin Approved Phase 4 82419-36-1 4583
13
Azithromycin Approved Phase 4 83905-01-5 447043 55185
14
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
15
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
16
Travoprost Approved Phase 4 157283-68-6 5282226
17
Ethanol Approved Phase 4 64-17-5 702
18
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
19
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
20
Menthol Approved Phase 4 2216-51-5 16666
21
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
22
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
23
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
24
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
25
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
26 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
27
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
28
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
29
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
30
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
31
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
32
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
33
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
34
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
35
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
36
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4 8001-79-4
37 Tocotrienol Investigational Phase 4 6829-55-6
38
Rebamipide Investigational Phase 4 90098-04-7
39
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
40 Tocopherols Phase 4
41 Tocotrienols Phase 4
42 Calciferol Phase 4
43 Retinol palmitate Phase 4
44 retinol Phase 4
45 Analgesics, Non-Narcotic Phase 4
46 Analgesics Phase 4
47 Anti-Inflammatory Agents, Non-Steroidal Phase 4
48 Anti-Infective Agents, Local Phase 4
49 Plasma Substitutes Phase 4
50 Blood Substitutes Phase 4

Interventional clinical trials:

(show top 50) (show all 635)
# Name Status NCT ID Phase Drugs
1 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
2 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
3 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
4 A Randomized Masked Evaluation of Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
5 Tear Osmolarity Over Time With Artificial Tears Unknown status NCT01227226 Phase 4 Artificial tears
6 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
7 Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity in Dry Eye Disease (DED) With Meibomian Gland Dysfunction (MGD). Unknown status NCT02992535 Phase 4
8 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
9 A Phase IV, Prospective, Open-label, Multicentre, Single Arm, 3-month Proof of Concept Study to Assess the Effect of IKERVIS® Eye Drops Administered Once Daily on the Quality of Vision in Dry Eye Disease (DED) Patients With Severe Keratitis Unknown status NCT03237936 Phase 4 1mg/mL ciclosporin
10 Eight Week Feasibility Study Enrolling Dry Eye Subjects Confirmed by Four of Seven Dianostic Markers Responding to Nutritional Therapy Unknown status NCT01561040 Phase 4
11 A Single-Center Evaluation of Retaine™ Ophthalmic Emulsion in the Management of Tear Film Stability and Ocular Surface Staining in Patients Diagnosed With Dry Eye Completed NCT02139033 Phase 4 Retaine™
12 Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis Completed NCT00357019 Phase 4 N-acetyl-aspartyl-glutamate (NAAXIA Sine)
13 A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis Completed NCT03464435 Phase 4 Tacrolimus
14 Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Completed NCT01179412 Phase 4 2% povidone-iodine;2% povidone-iodine
15 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
16 The Effect of Kynex Versus Refresh Plus in Subjects With Mild to Moderate Dry Eye - A Parallel Group, Randomized, Masked Study Completed NCT00809198 Phase 4
17 A Comparison of Optive in Patients Previously Using Systane for the Treatment of Dry Eye Completed NCT00399230 Phase 4 Optive
18 Efficacy of Systane Balance to Stabilize the Tear Film in Dry Eye Subjects Completed NCT01086774 Phase 4
19 Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye Completed NCT00724412 Phase 4
20 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Completed NCT01684436 Phase 4
21 Effects of Conventional Dry Eye Treatments on the Ocular Surface Response to Low Humidity Environment in Patients With Keratoconjunctivitis Sicca. Completed NCT01797822 Phase 4 Dexamethasone;Artificial tear
22 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
23 A Randomized, Single-Center, Comparative Study of Rohto Dry-Aid® and Systane® Ultra in the Management of Tear Film Stability and Visual Function in Patients With Dry Eye Completed NCT03183089 Phase 4 Rohto Dry-Aid®;Systane® Ultra
24 Comparison of Tear Evaporation Rate With Systane Complete in Dry Eye and Non-Dry Eye Completed NCT04091581 Phase 4 Systane Complete
25 Evaluation of the Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz Completed NCT01742884 Phase 4
26 Bromfenac 0.09% vs. Ketorolac 0.4% During the Induction Phase of Treatment With Topical Cyclosporine for Chronic Dry Eye Patients Completed NCT00520260 Phase 4 bromfenac;ketorolac
27 Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease Completed NCT00567177 Phase 4 Restasis, Refresh Plus
28 Efficacy of Systane Ultra in Post Menopausal Women With Dry Eye Completed NCT01105910 Phase 4
29 Evaluation of the Repeated Usage of Systane Ultra Eyedrop Completed NCT01051804 Phase 4
30 Topical Cyclosporine in the Treatment of Vernal Keratoconjunctivitis in a Rwandan Eye Clinic; a Prospective Randomized Double-masked Clinical Trial Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
31 A Prospective, Multicenter, Randomized Controlled Study of the Effect of Lotepredol Etabonate on The Initiation of Dry Eye Treatment With Topical Cyclosporine Completed NCT00407043 Phase 4 Lotemax;Restasis
32 Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms Completed NCT00761202 Phase 4 A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®;Sodium hyaluronate
33 Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00405457 Phase 4 Restasis, Optive Tears
34 Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00399061 Phase 4 Systane, Optive, Restasis
35 Efficacy of Topical Cyclosporine Ophthalmic Emulsion for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Completed NCT00349440 Phase 4 Cyclosporine, Refresh Plus
36 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
37 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality Completed NCT00622037 Phase 4 PEG-400 based artificial tear;Systane
38 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients Completed NCT01682460 Phase 4 Refresh Tears Lubricant Eye Drops (Allergan)
39 Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes Completed NCT00469573 Phase 4 1. Optive
40 A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms Completed NCT02028754 Phase 4 Sodium Carboxymethylcellulose;Levofloxacin;Prednisolone
41 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products Completed NCT02014922 Phase 4 TheraTears® Lubricant Eye Drop;TheraTears® preservative-free single-use containers
42 A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes Completed NCT00781092 Phase 4
43 Comparison of Systane Free vs. Saline in the Treatment of Dry Eye Completed NCT00388791 Phase 4 Systane Free
44 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Completed NCT01014078 Phase 4 Azithromycin Ophthalmic Solution, 1%;Placebo
45 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE) Completed NCT01105624 Phase 4 azithromycin ophthalmic solution, 1%;Visine® for Contacts®
46 A Randomized Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens Completed NCT01061268 Phase 4 No topical artificial tear;Blink® Tears Lubricant Eye Drops
47 Multi-Site Post Marketing Surveillance Study for Systane in Indian Patients Completed NCT01311609 Phase 4
48 Evaluation of the Effect of Repeated Usage of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints Completed NCT01543061 Phase 4
49 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms Completed NCT00938704 Phase 4 carboxymethylcellulose 0.5% +glycerin 0.9%;sodium hyaluronate 0.18%
50 A Prospective, Double-masked, Placebo Controlled Comparison of Topical 0.15% Ganciclovir Gel (Zirgan®) Versus 0.3% Hypromellose Gel (Genteal Gel®; Placebo) for the Treatment of Adenovirus Conjunctivitis Completed NCT01533480 Phase 4 Zirgan;genteal gel

Search NIH Clinical Center for Keratoconjunctivitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Lodoxamide
lodoxamide tromethamine

Cochrane evidence based reviews: keratoconjunctivitis

Genetic Tests for Keratoconjunctivitis

Anatomical Context for Keratoconjunctivitis

MalaCards organs/tissues related to Keratoconjunctivitis:

40
Eye, Testes, T Cells, Salivary Gland, Thyroid, Bone, Bone Marrow

Publications for Keratoconjunctivitis

Articles related to Keratoconjunctivitis:

(show top 50) (show all 4458)
# Title Authors PMID Year
1
Ocular complications of autoimmune polyendocrinopathy syndrome type 1. 54 61
17189144 2006
2
Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. 54 61
10682966 2000
3
Tear levels of interferon-gamma, interleukin (IL) -2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis. 61 54
10606937 2000
4
Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease. 54 61
10469030 1999
5
Presence of eotaxin in tears of patients with atopic keratoconjunctivitis with severe corneal damage. 61 54
10359913 1999
6
Complicated case of Mycobacterium abscessus conjunctivitis in Sjögren's syndrome. 61
32548334 2020
7
Corneal melt in conjunctival intraepithelial neoplasia. 61
32426552 2020
8
Clinical Profile of Bilateral Microsporidial Keratoconjunctivitis in Healthy Individuals-A Case Series With Long-term Follow-up. 61
32141940 2020
9
A Narrative Review of Microsporidial Infections of the Cornea. 61
32157613 2020
10
Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment. 61
31554632 2020
11
Prospective Clinical Study of Keratoconus Progression in Patients Awaiting Corneal Cross-linking. 61
32482959 2020
12
Ocular Surface Disorders in Patients with Human Immunodeficiency Virus (HIV) Infection. 61
32501744 2020
13
Dupilumab therapy in a patient with atopic dermatitis and severe atopic keratoconjunctivitis. 61
32031716 2020
14
Risk of recurrent corneal erosion in patients with diabetes mellitus in Taiwan: a population-based cohort study. 61
32565466 2020
15
Ocular allergy test and biomarkers on the ocular surface: Clinical test for evaluating the ocular surface condition in allergic conjunctival diseases. 61
32563624 2020
16
Rapid differentiation of Moraxella bovoculi genotypes 1 and 2 using MALDI-TOF mass spectrometry profiles. 61
32418912 2020
17
Association between atopic keratoconjunctivitis and the risk of keratoconus. 61
32567209 2020
18
Hidradenitis Suppurativa is Associated with Symptoms of Keratoconjunctivitis Sicca. 61
32506959 2020
19
Ocular Anterior Segment Pathology in the Emergency Department: A 5-Year Study. 61
32568931 2020
20
Environmental relative humidity affects Schirmer tear test results in normal dogs. 61
32573896 2020
21
Salivary gland ultrasound in the diagnostic workup of juvenile Sjögren's syndrome and mixed connective tissue disease. 61
32517804 2020
22
Role of combined immunomodulator therapy in severe steroid intolerant vernal keratoconjunctivitis. 61
32518397 2020
23
[Vernal keratoconjunctivitis (VKC) successfully treated with omalizumab]. 61
32381370 2020
24
Late-term topical tacrolimus for subepithelial infiltrates resistant to topical steroids and ciclosporin secondary to adenoviral keratoconjunctivitis. 61
32563992 2020
25
Surgical debridement of corneal shield ulcers in pediatric patients: two case reports and a review of the literature. 61
32546209 2020
26
Ocular surface disease associated with dupilumab treatment for atopic diseases. 61
32439390 2020
27
Long-term Outcome of Punctal Cauterization in the Management of Ocular Surface Diseases. 61
32467449 2020
28
Standard cross-linking protocol versus accelerated and transepithelial cross-linking protocols for treatment of paediatric keratoconus: a 2-year comparative study. 61
31654497 2020
29
Outcome of intensity-modulated radiation therapy-based stereotactic radiation therapy for treatment of canine nasal carcinomas. 61
32189433 2020
30
Ocular manifestations in rheumatoid arthritis, connective tissue disease and vasculitis: a systematic review and meta-analysis. 61
32358156 2020
31
COVID-19: Ophthalmological Aspects of the SARS-CoV 2 Global Pandemic. 61
32375197 2020
32
Immunobiology of T Cells in Sjögren's Syndrome. 61
32390096 2020
33
Evaluation of partial tarsal plate excision using a transconjunctival approach for the treatment of distichiasis in dogs. 61
32083378 2020
34
Mystery eye: Human adenovirus and the enigma of epidemic keratoconjunctivitis. 61
31891773 2020
35
Corneoconjunctival transposition for the treatment of deep stromal to full-thickness corneal defects in dogs: A multicentric retrospective study of 100 cases (2012-2018). 61
31950569 2020
36
Finger-Prick Autologous Blood in the Treatment of Persistent Corneal Epithelial Defects. 61
31868852 2020
37
Effect of Oral Choline Alfoscerate on Patients with Keratoconjunctivitis Sicca. 61
32456260 2020
38
Efficacy of adjunctive therapy using Vizoovet in improving clinical signs of keratoconjunctivitis sicca in dogs: A pilot study. 61
32386123 2020
39
[Assessment of Langerhans Cells in the Central Cornea as Tool for Monitoring Inflammatory Changes in Patients with Keratoconjunctivitis sicca under Topical Therapy with Cyclosporine A 0.05% Eye Drops]. 61
32434251 2020
40
Epidemic Keratoconjunctivitis in India: Trend Analysis and Implications for Viral Outbreaks. 61
32317436 2020
41
Characteristic of slow growth in cell culture of adenovirus type 54 causing nationwide outbreak epidemic keratoconjunctivitis in Japan. 61
32125553 2020
42
Tear cytokine profiling in patients with superior limbic keratoconjunctivitis who underwent medical treatment or in conjunction with surgical management. 61
30926588 2020
43
Severe vernal keratoconjunctivitis complicated by anaesthetic abuse. 61
32456789 2020
44
Commentary: Adenoviral keratoconjunctivitis-Seasonal trends and influence of environmental factors. 61
32317437 2020
45
Bacterial keratoconjunctivitis caused by Staphylococcus argenteus belonging to sequence type 1223 isolated in Japan. 61
32471795 2020
46
Pattern of corneal disorders in Ekiti: A tertiary eye center experience. 61
32499468 2020
47
Design and Outcomes of a Novel Keratoprosthesis: Addressing Unmet Needs in End-Stage Cicatricial Corneal Blindness. 61
31724985 2020
48
Twelve-Month Results of Cyclosporine A Cationic Emulsion in a Randomized Study in Patients With Pediatric Vernal Keratoconjunctivitis. 61
31770513 2020
49
Clinical Profile in Genetically Proven Blau Syndrome: A Case Series from South India. 61
32293936 2020
50
Corneal Microstructural Changes by Confocal Microscopy in Vernal Keratoconjunctivitis Patients Treated with Topical Cyclosporine. 61
32275180 2020

Variations for Keratoconjunctivitis

Expression for Keratoconjunctivitis

Search GEO for disease gene expression data for Keratoconjunctivitis.

Pathways for Keratoconjunctivitis

Pathways related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 TNF RNASE3 MUC5AC MUC16 MMP9 IL6
2
Show member pathways
13.93 TNF NGF IL6 IL5 IL4 IL3
3
Show member pathways
13.79 TNF NGF IL6 IL5 IL4 IL3
4
Show member pathways
13.64 TNF NGF IL6 IL5 IL4 IL3
5
Show member pathways
13.53 TNF NGF IL6 IL5 IL4 IL3
6
Show member pathways
13.46 TNF MMP9 IL6 IL5 IL4 IL3
7
Show member pathways
13.43 TNF NGF IL6 IL5 IL4 IL3
8
Show member pathways
13.11 TNF MMP9 IL6 IL2 IFNG CXCL8
9
Show member pathways
13.05 TNF NGF IL6 IL4 IL3 IL2
10 13 MMP9 IL6 IL5 IL4 IL3 IL2
11
Show member pathways
12.94 TNF IL6 IL2 IFNG ICAM1 CXCL8
12
Show member pathways
12.76 TNF NGF IL6 IL3 IL2
13
Show member pathways
12.76 TNF IL6 IL5 IL4 IL2 IL17A
14
Show member pathways
12.74 TNF IL6 IL5 IL4 IL2 IL17A
15 12.71 TNF IL4 IL3 IL2 IL17A IFNG
16
Show member pathways
12.66 TNF IL6 IL2 IL17A IFNG
17
Show member pathways
12.65 TNF IL5 IL4 IL3 IL13
18
Show member pathways
12.64 TNF IL4 IL3 IL2 IFNG ICAM1
19
Show member pathways
12.59 IL6 IL5 IL4 IL3 IL2 IL13
20
Show member pathways
12.47 TNF IL6 IL2 CXCL8 CCL24 CCL11
21
Show member pathways
12.47 TNF IL6 IL4 IL2 IFNG ICAM1
22
Show member pathways
12.4 ICAM1 CXCL8 CCL24 CCL11
23 12.39 TNF IL6 IL2 ICAM1
24
Show member pathways
12.34 TNF IL6 IL4 IFNG CXCL8 CCL11
25 12.33 MMP9 IL6 IL3 CXCL8
26
Show member pathways
12.32 TNF NGF IL6 IL5 IL4 IL3
27 12.3 TNF NGF IL6 IL13 CXCL8
28 12.26 TNF MMP9 IL6 IFNG
29 12.18 TNF IL6 IL5 IL4 IL3 IL2
30
Show member pathways
12.18 TNF RNASE3 IL6 IL5 IL4 IL3
31 12.17 TNF MMP9 IFNG ICAM1
32 12.16 TNF MMP9 IL6 IL4 IL2 IFNG
33 12.1 TNF IL6 IL2 CXCL8
34
Show member pathways
12.1 TNF IL6 IL2 IL17A IFNG
35 12.07 TNF MMP9 IL6 ICAM1
36 12.06 TNF IL6 IL5 IL4 IL3
37 12.06 TNF IL6 IL17A IFNG ICAM1 CXCL8
38 12.04 IL6 IL3 IFNG CXCL8
39
Show member pathways
12.03 TNF MUC5AC MMP9 IL6 IL5 IL4
40 12.02 TNF IL6 IFNG CXCL8
41 12.01 TNF IL6 ICAM1 CXCL8
42
Show member pathways
11.97 IL6 IL17A ICAM1 CXCL8
43 11.97 TNF IL5 IL4 IL2 IL17A IL13
44 11.97 IL6 IL5 IL4 IL2 IL13 IFNG
45 11.97 TNF MMP9 IL6 IL4 IL17A IL13
46
Show member pathways
11.96 IL6 IL4 IL17A IFNG
47
Show member pathways
11.94 TNF IL5 IL4 IL3 IL2 IFNG
48 11.87 TNF IL6 IL2 IFNG
49
Show member pathways
11.84 TNF MMP9 IL6 IL2 IFNG ICAM1
50 11.81 TNF IL6 CXCL8

GO Terms for Keratoconjunctivitis

Cellular components related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.89 TNF RNASE3 NGF MUC5AC MUC16 MMP9
2 extracellular space GO:0005615 9.58 TNF RNASE3 NGF MUC5AC MUC16 MMP9

Biological processes related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

(show all 50)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10.1 IL6 IL5 IL4 IL3 IL2 IFNG
2 cell-cell signaling GO:0007267 10.01 IL3 IL2 IL17A CCL24
3 positive regulation of gene expression GO:0010628 10 TNF NGF IL6 IL4 IL13 IFNG
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.98 TNF ICAM1 CCL24 CCL11
5 positive regulation of protein phosphorylation GO:0001934 9.97 TNF MMP9 IL2 IFNG
6 cellular response to lipopolysaccharide GO:0071222 9.97 TNF IL6 ICAM1 CXCL8
7 cellular response to tumor necrosis factor GO:0071356 9.93 ICAM1 CXCL8 CCL24 CCL11
8 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.88 IL6 IL5 IL3 ICAM1
9 neutrophil chemotaxis GO:0030593 9.87 CXCL8 CCL24 CCL11
10 chemokine-mediated signaling pathway GO:0070098 9.86 CXCL8 CCL24 CCL11
11 inflammatory response GO:0006954 9.86 TNF IL6 IL5 IL17A IL13 CXCL8
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.85 TNF IL6 IL13
13 positive regulation of inflammatory response GO:0050729 9.85 TNF IL2 IFNG CCL24
14 positive regulation of actin filament polymerization GO:0030838 9.84 ICAM1 CCL24 CCL11
15 positive regulation of T cell proliferation GO:0042102 9.83 IL6 IL4 IL2 CD46
16 monocyte chemotaxis GO:0002548 9.82 IL6 CCL24 CCL11
17 positive regulation of nitric oxide biosynthetic process GO:0045429 9.82 TNF IFNG ICAM1
18 positive regulation of interleukin-6 secretion GO:2000778 9.81 TNF IL17A IFNG
19 negative regulation of endothelial cell apoptotic process GO:2000352 9.8 IL4 IL13 ICAM1
20 humoral immune response GO:0006959 9.8 TNF IL6 IFNG AIRE
21 positive regulation of JAK-STAT cascade GO:0046427 9.78 TNF IL6 IL5
22 negative regulation of neurogenesis GO:0050768 9.77 TNF IL6 CCL11
23 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.74 TNF IL6 IL17A
24 positive regulation of osteoclast differentiation GO:0045672 9.73 TNF IL17A IFNG
25 cytokine-mediated signaling pathway GO:0019221 9.73 TNF MMP9 IL6 IL5 IL4 IL3
26 cellular response to interleukin-1 GO:0071347 9.72 IL17A ICAM1 CXCL8 CCL24 CCL11
27 positive regulation of interleukin-10 secretion GO:2001181 9.71 IL4 IL13
28 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.71 TNF IL6 ICAM1
29 positive regulation of B cell proliferation GO:0030890 9.71 IL5 IL4 IL2 IL13
30 regulation of neuroinflammatory response GO:0150077 9.7 MMP9 IL6
31 positive regulation of mast cell degranulation GO:0043306 9.7 IL4 IL13
32 negative regulation of amyloid-beta clearance GO:1900222 9.7 TNF IFNG
33 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.7 TNF IL6 IL4 IL3 IL2 IL13
34 positive regulation of isotype switching to IgG isotypes GO:0048304 9.69 IL4 IL2
35 positive regulation of MHC class II biosynthetic process GO:0045348 9.69 IL4 IFNG
36 negative regulation of lipid storage GO:0010888 9.69 TNF IL6
37 positive regulation of chemokine biosynthetic process GO:0045080 9.69 TNF IL4 IFNG
38 negative regulation of T-helper 17 cell differentiation GO:2000320 9.68 IL4 IL2
39 positive regulation of mononuclear cell migration GO:0071677 9.67 TNF IL4
40 microglial cell activation GO:0001774 9.67 TNF IL4 IL13 IFNG
41 positive regulation of cellular respiration GO:1901857 9.66 IL4 IFNG
42 neuroinflammatory response GO:0150076 9.65 IL4 IFNG
43 positive regulation of interleukin-23 production GO:0032747 9.65 IL17A IFNG
44 positive regulation of immunoglobulin secretion GO:0051024 9.65 IL6 IL5 IL2
45 negative regulation of complement-dependent cytotoxicity GO:1903660 9.62 IL4 IL13
46 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.61 TNF IFNG
47 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.61 TNF IL17A IFNG
48 positive regulation of vitamin D biosynthetic process GO:0060557 9.59 TNF IFNG
49 positive regulation of nitrogen compound metabolic process GO:0051173 9.58 TNF IFNG
50 immune response GO:0006955 9.44 TNF IL6 IL5 IL4 IL3 IL2

Molecular functions related to Keratoconjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.28 TNF NGF MUC5AC MUC16 MMP9 IL6
2 chemokine activity GO:0008009 9.43 CXCL8 CCL24 CCL11
3 growth factor activity GO:0008083 9.43 NGF IL6 IL5 IL4 IL3 IL2
4 cytokine activity GO:0005125 9.4 TNF IL6 IL5 IL4 IL3 IL2
5 CCR3 chemokine receptor binding GO:0031728 9.16 CCL24 CCL11

Sources for Keratoconjunctivitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....